that mouse basophils play a key role in IgG-mediated, but not IgEmediated, anaphylaxis. Subsequently, a report from the group headed by Marc Daëron provided the evidence of a substantial subpopulation of human basophils that express CD16b. 10 The CD16a (FcγRIIIA) and CD16b (FcγRIIIB) surface antigens are low-affinity IgG receptors. CD16a, the activating IgG receptor, commonly serves as a marker of NK cells, NKT cells, monocytes and macrophages and is also present on eosinophils, reactive T cells, immature thymocytes and placental trophoblast cells. CD16b is the most abundant low-affinity IgG receptor on multiple types of leucocytes, but its functions remain unclear. 4, 11 In contrast to previous reports, Daëron and colleagues claimed that 24%-81% (median 44%) of basophils from healthy men express CD16b transcripts. Additionally, these authors showed the expression of CD16b transcripts in basophils from patients with various allergic diseases, with similar levels experienced in patients with respiratory allergy (median 57%) and chronic urticaria (median 34%) and significantly decreased levels in atopic dermatitis patients (22%), without any correlation with the sex or age of the patients or their serum IgE levels. Their report was based on the analysis of CD16a and CD16b transcripts instead of the proteins because the currently used αCD16 antibodies, such as 3G8 or LNK16, do not discriminate between the two isoforms. 10 Using staining for the two above-mentioned antibody clones, Daëron and colleagues showed that a subset of human basophils expressed low but detectable levels of the CD16 protein. The expression levels were lower by one or two orders of magnitude when compared to those in monocytes, NK cells or neutrophils. By cleaving the GPI anchor of CD16 with phosphatidylinositol-specific phospholipase C (PI-PLC), these authors showed that the detected CD16 protein indeed represents glycophosphatidylinositol (GPI)-anchored CD16b
and not transmembrane CD16a. 10 Under most of the experimental setups, cell activation decreases the (surface) expression of CD16b, 12 which was also reported from human basophils stimulated with αIgE. 10 Importantly, antibodies against CD16 were often included in the negative selection cocktails used for the enrichment of basophils; thus, the CD16-positive basophils may be absent from many previous analyses of their functions. 7, 13 According to Salvatore Chirumbolo, 5 it is paradoxical that there are no published BAT that would corroborate and further expand the initial observation of CD16b downregulation by the FcεRI-IgEmediated activation of basophils, despite reports showing a basophil desensitization following omalizumab immunotherapy. 14 The omalizumab therapy of patients with allergy blocks the increase in
CD203c following the stimulation of basophils. 15 If the CD16b surface expression is coupled with the CD203c, but not CD63 surface expression, then it should respond to the application of inhibitors that specifically block CD203c surface expression but enable CD63 surface expression during antigen-induced basophil activation. These effects have been previously reported as side effects of the protein kinase C (PKC) inhibitors bisindolylmaleimide II and Ro 31-8220.
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CD203c is an ecto-nucleotide pyrophosphatase/phosphodiesterase with an unknown physiological role, the surface expression of which is rapidly upregulated following the basophil activation in a manner more rapid than that of CD63. The surface expression of CD203c and CD63 in αIgE-stimulated cells was insensitive to the two abovementioned PKC inhibitors when applied at the half-maximal inhibitory concentration (IC 50 ) of the PKC itself (~100 nM). In contrast, the 3 μM concentration of the same inhibitors led to a differential increase in the surface expression of CD203c (15-fold) when compared to that of CD63 (2-fold) and the release of histamine (1.5-fold) when stimulated by Ro-81-3220 with αIgE; with slightly less pronounced differences also obtained when applying bisindolylmaleimide II with αIgE. 16, 17 The mechanisms of this regulation are unclear, independent from the activation and/or translocation of PKC. However, this regulation of CD63 surface expression suggests the existence of multiple forms of granules in peripheral blood basophils as previously suggested by electron microscopy experiments. Thus, decoupling CD63
and CD203c externalization enables an examination of the coupling of CD16b and CD203c surface expression suggested above.
Here, we hypothesized that (a) a fraction of human basophils | 55
basophils. The present study is the first to corroborate the initial findings of Marc Daëron and colleagues, 10 showing CD16 expression on the surface of human basophils and the first to implement the concept of differential CD203c and CD63 regulation by supraoptimal concentrations of the PKC inhibitors initially suggested by Donald W. MacGlashan Jr. 16 We provide the first evidence of the response of CD16 surface expression to naturally occurring stimuli, such as birch pollen allergen, and bee and wasp venom extracts, and show the first analysis of the expression of this marker in patients with venom or pollen allergy.
| MATERIALS AND METHODS

| Study population
We recruited three independent cohorts of adult (23-77 years) human subjects of Czech nationality, who provided written informed consent for BAT. The informed consent form and experiments were approved by the Ethics Committee of the Third Faculty of Medicine, Charles University; the approval was not numbered and was issued on April 4, 2018. The study conforms to the standards of the Declaration of Helsinki. The absolute exclusion criteria included the use of antihistamines or oral steroids within 4 days prior to the challenge.
We screened the following cohorts:
(1) Patients with the history of anaphylaxis to Hymenoptera (bee or wasp) venom of grade II to IV as classified according to the H.
Mueller schedule, positive skin test results and/or elevated specific IgE levels (n = 16, of these 12 patients with reactions to wasp venom and 4 patients with reactions to bee venom).
(2) Patients reporting subjective birch pollen allergy symptoms, objective allergy signs on conjunctival and nasal mucosa, and with records of positive skin prick test (≥3 mm) for birch pollen allergen or elevated IgE specific to birch pollen allergen (n = 5).
(3) Control subjects without any known history of asthma, allergy and anaphylaxis (n = 10).
We did not apply any relative exclusion criteria based on the ratios of cells positive for basophil activation markers. There were no blood specimens with negative results in αIgE stimulations; thus, no patients were excluded from the presentation and statistical analyses. For the αIgE positive control, we determined the cut-off values by adding the double standard deviation value of CD63 + basophils observed in patients' background tubes to the mean value.
| The application of PKC inhibitors
We applied two PKC inhibitors, bisindolylmaleimide II (Santa Cruz Biotechnology, Santa Cruz, CA) and Ro-31-8220 (Merck, Darmstadt, Germany), which were previously reported to alter the ratio of CD193 and CD203c at the surface of basophils when used at low micromolar concentrations, 16 and which thus were thought to enable the differential surface exposure of a specific type of basophil granules. We observed the previously reported effects on the change of CD193 and CD203c ratios when using 3. We stored the cells on ice and immediately measured them at 
| BAT coupled with ex vivo histamine release
ELISA assay
To corroborate the outcomes of BAT, we coupled BAT with the ex vivo histamine release ELISA assay. We tested six human volun- We measured the histamine content using the ELISA assay (RE59221, IBL International, Hamburg, Germany) according to manufacturer's instructions. The assay was based on the competition principle, when the tested histamine was competing for binding sites on the αhistamine antibody-coated wells with a fixed amount of enzyme-labelled antigen. We tested a standard curve of histamine in a range from 0.35 to 150 ng/mL. It revealed that the method was somewhat less sensitive compared to the manufacturer's instructions and we considered only histamine concentrations >0.5 ng/mL as reproducibly detectable. We measured all samples in duplicates; the intra-assay variability was 13.1%.
| CD16b cleavage
To differentiate between the CD16a and CD16b isoforms at the protein level, the GPI cleavage can be employed since only the CD16b isoform is GPI-attached, whereas the CD16a isoform is con- To amplify mRNA for CD16, we isolated total RNA from sorted cells using PicoPure RNA isolation kit (ThermoFisher Scientific, Waltham, MA) and immediately prepared cDNA using SuperScript VILO cDNA Synthesis kit (Invitrogen, Carlsbad, CA). We subsequently amplified the desired sequences using two series of primers. The first set of primers had a nested design and aimed to detect a short DNA locus that contains several single-nucleotide polymorphisms when comparing mRNAs for CD16a and CD16b. The second set of primers had a semi-nested design and aimed to detect specifically mRNA for CD16a isoform only. The third set of primers had a nested design and served as a positive control by means of detecting the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) Table S2 . We amplified the fragments using Q5 Hot Start DNA Polymerase (New England Biolabs, Ipswich, MA); with negative controls prepared for all reactions. We subsequently sequenced the CD16 amplicons bidirectionally using an ABI 3130 DNA Analyzer (Applied Biosystems, Foster City, CA) and searched for matching CD16a and CD16b sequences using NCBI Blast.
| Data analyses
We analyzed the flow data using CellQuest (BD Biosciences, San
Jose, CA . We did not stain the cells with any antibodies and identified the populations of monocytes/ macrophages and lymphocytes based on their SSC and FSC fluorescence. We tested the significance of observed changes by Kruskal-Wallis ANOVA on ranks (as the data did not pass Shapiro-Wilk normality test) followed by Dunnett's post-tests that compared the respective values with the mock-treated control. Asterisks indicate significant differences at α = 0.05 F I G U R E 3 Apparent changes in CD16 and CD63 fluorescence caused by the application of supraoptimal concentrations of the PKC inhibitors Ro-31-8220 (3 μM) (A) and bisindolylmaleimide II (3.5 μM) (B). We treated the cells isolated from controls without allergy, from cases with allergy to Hymenoptera venoms, and cases with allergy to birch pollen with the two inhibitors or mock and activated them with αIgE or mock. Median, modus and share of cells positive for the respective antigen are indicated together with the gating strategies used. We compared the fluorescence signals to those obtained when using cells that we did not expose to the PKC inhibitors. Asterisks indicate groups with significant differences at α = 0.05 as revealed by Kruskal-Wallis ANOVA on ranks concentrations was sufficient to induce changes in the apparent fluorescence of CD63-FITC and CD16-PerCP, whereas the robust signal of CD193 and CD203 was only marginally affected.
| CD16 is newly confirmed as a surface antigen on human basophils
Previously + (E,F) cells. We analyzed separately cells from controls without allergy, patients with allergy to Hymenoptera venoms and patients with allergy to birch pollen. We analyzed the cells activated by the αIgE-mediated FcεRI crosslink, Hymenoptera venom extracts (except cells from patients with allergy to birch pollen) and the major birch pollen allergen Bet v 1a (except cells from patients with allergy to Hymenoptera venoms) or mock-treated. Asterisks indicate groups with significant differences at α = 0.05 as revealed by Kruskal-Wallis ANOVA on ranks or MannWhitney rank sum tests in case when we compared only two groups surface expression at the protein level. In contrast, we found that mRNA for CD16b isoform is also expressed by basophils but only at low level (CD16 dim basophils); we did not find mRNA for the CD16b isoform in CD16 + and CD16 − basophils despite the same nested RT-PCR approach amplified CD16b as the only detectable CD16 isoform in the CD16 + neutrophils ( Figure 5 ).
We obtained similar results at the protein level. The PI-PLCmediated cleavage of the GPI-anchored isoform CD16b revealed that this isoform is dominant on neutrophils that served as a positive control. Nevertheless, the PI-PLC treatment did not stimulate the decrease of CD16 signal on basophils from patients with the history of bee venom anaphylaxis as well as from control subjects when treated with αIgE, bee venom extract or mock (Table S4 ). The experiment that involved PI-PLC-mediated cleavage suggested that CD16b
may not be considered a dominant CD16 isoform on basophils of any of the tested patients and control subjects. CD203c over CD63 and histamine in response to interleukin-3, [24] [25] [26] prostaglandin D2 27 and phorbol myristate acetate. 28 We corroborated the surprising and previously unverified finding a large fraction of basophils, and the number of CD16-expressing basophils was increased to a larger extent in response to the stimulation with allergen or by FcεRI crosslinking (Figure 4 ). In contrast, the patients with respiratory allergy to birch pollen had numbers of CD16-expressing basophils similar to those in healthy controls both before and after the activation of the basophils. Thus, the present study supports the assumption that multiple methods of basophil enrichment by using elutriation and/or sorting based on antigenic features, for which the basophils are considered as negative, may lead to the depletion of specific basophil populations expressing CD16. CD16 + cells are particularly abundant among activated basophils, and among those that express high CD63 levels even on resting cells (Figure 4 ).
| DISCUSSION
Unexpectedly, we found that at the mRNA as well as at the protein level, the dominant CD16 form, which is expressed on human basophils, is CD16a. This contradicts the data by Marc
Daëron and colleagues, who concluded that only CD16b is expressed in this cell type. 10 Despite they amplified mRNA for CD16, they did not verify to which isoforms it belongs and their conclusion was based solely on the PI-PLC-mediated GPI cleavage of the CD16b anchor. We employed the same method, optimized it in a way that we reached more striking decreases of CD16b fluorescence on neutrophils (serving as a positive CD16b control) compared to those reported by Daëron and colleagues but still we did not see any major changes of the CD16 fluorescence on basophils.
It is possible that there may be differences at the individual level as there are indices that the presence of certain CD16a polymorphisms may increase CD16a expression in NK cells. 29, 30 Nevertheless, among the six patients and control subjects tested in the present study, we did not see any that would express CD16b as a dominant form of surface-bound CD16 (Table S4) . We reproduced these unexpected findings at the mRNA level, where we confirmed by Sanger sequencing of nested RT-PCR products that CD16a is the dominant form of CD16 in basophils although we also detected low expression of CD16b ( Figure 5 ). Combined, these results unanimously suggest that CD16a is a dominant CD16 isoform in human basophils.
Previously, CD16 + cells were reported to represent 24%-81% basophils from control subjects and 12%-100% basophils from patients with allergies. 10 However, the same report, which claimed such a high positivity, showed only a single scatter plot that allows directly observing the CD16 gating strategy used. 10 From the only figure shown, it can be speculated that any fluorescence >10 1 RFU was considered a positive signal when evaluating the fluorescence of αCD16 antibody conjugates.
Despite that, their αCD16 signal on neutrophils was approximately at 10 3 RFU and there were only a few basophils that reached this signal, if any ( Figure 4A in Ref. [10] ). Thus, to be able to compare directly the outcomes of the present study with those by Marc Daëron and colleagues, 10 we would need to summarize the data reported in the present study as both CD16 + and CD16 dim . Such alternatively processed data do not differ from those reported previously. In the present study, we, for example, reached 13.4%-35.0% share of CD16 +/dim cells among basophils from the three control subjects tested in the experiment with PI-PLC, and 8.8%-16.6% share of CD16 +/dim cells among basophils from the three patients with the history of bee venom anaphylaxis tested in the experiment with PI-PLC (Table S4) . Combined, these results suggest that dim expression of CD16 is a common feature of human basophils but only a rare subpopulation of basophils expresses displays bright CD16 signal, which would be of similar intensity as that of CD16 on human neutrophils.
In conclusion, we rejected the apparent dissociation of the sur- 
